Tag: chRDNA

Phase 1 Trial to Test ‘Off-the-shelf’ CAR T-cell Therapy CB-011 in 2023 | CAR T-cell Therapy CB-011 to Be Tested in Hard-to-treat Myeloma in 2023

Caribou Biosciences will soon start testing its new CAR T-cell therapy candidate, CB-011, in people with relapsed or refractory multiple myeloma. A Phase 1 trial will begin enrolling eligible adults in early 2023 at multiple centers, according to the company. The announcement follows clearance of the company’s investigational new drug…

Continue Reading Phase 1 Trial to Test ‘Off-the-shelf’ CAR T-cell Therapy CB-011 in 2023 | CAR T-cell Therapy CB-011 to Be Tested in Hard-to-treat Myeloma in 2023

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences, Inc. BERKELEY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi 17th Annual BioPharma Conference, BostonPanel participation on September 8, 2022, 11:20 am ETWebcast H.C. Wainwright 24th…

Continue Reading Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences Announces – GuruFocus.com

BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. ( CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors. Mr. Johnson is a seasoned executive with 30 years of commercial and operational experience in the biopharmaceutical…

Continue Reading Caribou Biosciences Announces – GuruFocus.com

Caribou Biosciences to Present at Upcoming Investor Conferences

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer,…

Continue Reading Caribou Biosciences to Present at Upcoming Investor Conferences

Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17th,…

Continue Reading Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at…

Continue Reading Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the publication of data…

Continue Reading Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology

Caribou Biosciences Announces Publication of Data

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the publication of data…

Continue Reading Caribou Biosciences Announces Publication of Data

Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO | Rothwell, Figg, Ernst & Manbeck, P.C.

Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the most lucrative IPOs in gene-editing. In June 2021, Gene editing biotech Verve raised $267M in IPO proceeds and later added another $40 million after its financial underwriters opted to buy…

Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO | Rothwell, Figg, Ernst & Manbeck, P.C.